Stereotaxis Receives European CE Mark Approval For MAGiC Ablation Catheter, Enhancing Robotics In Electrophysiology With Advanced Navigation, Improved Data, And Low-Flow Cooling Benefits

Author: Benzinga Newsdesk | January 27, 2025 08:15am

Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it received European CE Mark approval for the MAGiC™ ablation catheter. This approval is a significant milestone for Stereotaxis and for the community of physicians pioneering robotics in electrophysiology. It is reflective of the company's commitment to advancing significant innovations that make robotics increasingly impactful across interventional medicine.

Stereotaxis' MAGiC catheter is a robotically-navigated magnetic ablation catheter designed to perform cardiac ablation procedures that treat heart arrhythmia. The MAGiC catheter was developed based on insights collected over the course of nearly 20 years and 150,000 robotic ablation procedures performed using predecessor catheters. The MAGiC catheter is designed to enhance treatment precision and control during cardiac ablation, while maintaining the intrinsic safety advantage of a soft flexible catheter. It builds upon existing benefits of robotic cardiac ablation with design enhancements that include:

• Optimized Navigation, Force & Stability – The unique placement of magnets and design of the distal section of the catheter supports intuitive navigation, consistent contact forces, and enhanced stability.
• Improved Data & Information – MAGiC is available with iConnect and the eContact module, offering catheter tissue contact information as well as clear electrogram and responsive temperature data to support physician decision making.
• Efficient Low-Flow Uniform Cooling – Cooling of the tip is accomplished with low-flow irrigation that substantially reduces overall fluid load on patients while protecting against char and coagulation.
  
   

The MAGiC catheter has been approved in Europe with a broad label that includes the delivery of "local lesions in cardiac tissue for the treatment of cardiac arrhythmias." Obtaining the CE Mark follows years of effort and substantial investments in catheter development, testing, manufacturing, and preclinical and clinical research. Clinical experience with MAGiC in an ongoing clinical study in Europe supports expectations for broad adoption of MAGiC across robotic users.

Posted In: STXS